Ollin Biosciences, a clinical-stage biotechnology firm, is set to unveil significant findings from its Phase 1b JADE clinical trial at the upcoming American Society of Retina Specialists (ASRS) Annual Scientific Meeting. The presentations will detail a head-to-head comparison of its investigational drug, OLN324, against the established therapy faricimab (Vabysmo). These results focus on treating patients with diabetic macular edema (DME) and neovascular age-related macular degeneration (wAMD), two leading causes of vision loss.
Upcoming Presentations at ASRS
The detailed results will be shared in two separate oral presentations during the ASRS meeting in Montreal, scheduled from July 15 to 18. Dr. David Eichenbaum will present the findings for neovascular AMD, while Dr. Veeral Sheth will discuss the outcomes for patients with diabetic macular edema. This platform provides a crucial opportunity for the medical community to review the promising data from the randomized, proof-of-concept study.
Superior Efficacy Demonstrated in JADE Trial
The JADE study's final data, initially announced in March 2026, indicated that OLN324 achieved meaningfully faster and more substantial anatomic improvements compared to faricimab. This was observed in patients with both DME and wAMD, highlighting the drug's potential across different patient populations. Furthermore, the trial showed that OLN324 led to numerically greater gains in vision, suggesting a potentially superior clinical benefit for patients.
The Science Behind OLN324
OLN324 is engineered as a next-generation VEGF/Ang2 bispecific antibody, building upon the proven success of dual-pathway inhibition in retinal diseases. Its design features substantially higher potency against Ang2, a key driver of vascular instability and inflammation, relative to faricimab. The drug also allows for a higher molar dose and has a smaller protein format, which could enhance its therapeutic effect within the eye.
The dual inhibition of both VEGF and Ang2 pathways is critical for treating complex retinal vascular conditions like DME and wAMD. While VEGF is a well-known target, Ang2 plays a significant role in vascular leakage, inflammation, and fibrosis that contribute to vision loss. By targeting Ang2 more potently, OLN324 aims to provide a more comprehensive and effective treatment to stabilize retinal vasculature and improve patient outcomes.
Path to Phase 3 and Market
Following the positive results from the Phase 1b trial, Ollin Biosciences is preparing to advance OLN324 into the next stage of clinical development. The company plans to initiate global Phase 3 trials for both DME and wAMD indications in the second half of 2026. This pivotal step moves the promising therapy closer to potentially becoming a new standard of care for patients with these vision-threatening diseases.
The development of OLN324 is a collaborative effort, with the drug being discovered by and developed in partnership with Innovent Biologics. Ollin Biosciences, established in 2023, is focused on acquiring and advancing best-in-disease therapies for ophthalmology. The company's progress with OLN324 underscores its commitment to redefining treatment possibilities through a differentiated pipeline and a world-class team.
The upcoming presentations at the ASRS meeting represent a pivotal moment for Ollin Biosciences and its lead candidate, OLN324. The compelling data from the JADE trial suggests a significant advancement in the treatment landscape for DME and wAMD, positioning OLN324 as a highly promising therapy. As the company moves toward Phase 3 trials, the ophthalmology community will be watching closely for further validation of its potential to improve patient vision.